Because of its implication in neuroprotection, formation of long lasting memories and a disturbed function in Alzheimer's disease (AD), brain-derived neurotrophic factor (BDNF) may represent an appropriate candidate gene conferring risk to AD. Recently, a single nucleotide polymorphism (C-270T) within the BDNF gene has been associated with late onset AD in a Japanese population giving an odds ratio (OR) of 3.8. Because of the importance of this finding we analysed the BDNF polymorphism in a German sample consisting of 210 patients with AD and 188 cognitively healthy controls. The Tallele frequency was higher in patients with AD (11.9%) compared to controls (6.9%) (P = 0.035; OR = 2.26; 95% CI: 1.04-4.48). The risk conferred by the T-allele was stronger in patients who lack the ApoE ⑀4 allele giving an OR of 2.61 (1.21-5.64) P = 0.015, particularly in patients with early onset of the disease; OR 3.13 (1.32-7.43); P = 0.01. Due to the small number of patients showing both, lack of the ApoE ⑀4 allele and the BDNF T allele (n = 18), the result needs to be confirmed in a larger sample. The results suggest that the BDNF C-270T polymorphism is a relevant risk factor for AD particularly in patients lacking the ApoE ⑀4 allele in this German sample.
Introduction
Neurotrophins such as brain-derived neutrophic factor (BDNF) play important roles in neuronal proliferation, differentiation, and survival during vertebrate development. [1] [2] [3] In the adult brain BDNF protects cholinergic neurons of the basal forebrain and neurons in the hippocampus from induced death. 4, 5 Furthermore at least in hippocampal regions BDNF is involved in the formation of long lasting memories. For establishment of long term potentiation (LTP), a widely studied model of memory, the induction of BDNF together with some other immediate early genes containing the cAMP response element is required. 6 Data from transgenics suggest that lack of BDNF or improper function is accompanied by seriously impaired learning and memory function. 7 Deficits in learning and memory are among the earliest clinical symptoms in patients with AD and linked to hippocampal and associated cortical pathologies. 8 Gene expression of BDNF has been shown to be reduced in hippocampal regions of patients with AD, 9 which might contribute to the described neuropsychological deficits. As a consequence of the reduced BDNF expression, protein levels are also decreased in several brain areas as demonstrated by Western blotting in post mortem AD brain. 10 Substitution of BDNF in mice led to an improvement of cognitive performance and, on the molecular level, to an enhancement of both synaptic strength and LTP in CA1 fields of the hippocampus. 11 Thus, application of BDNF may have therapeutic effects in patients with AD. 12 From these functional considerations BDNF may represent an appropriate candidate gene as genetic variations may confer risk to AD. In fact, a single nucleotide polymorphism within a non-coding region of the BDNF gene, located at 11p13 leading to a C→T substitution at position 270, has been described. 13 This polymorphism has been recently associated with late onset AD in a Japanese population. Heterozygous carriers of the T-allele were reported to have approximately a four times higher risk to develop AD than non-carriers (odds ratio (OR) 3.8). 13 The magnitude of this risk factor is almost comparable to the risk conferred by one copy of the apoE ⑀4 allele 14 which is the only genetic risk factor which has been unequivocally confirmed across several ethnic groups to date. Because of the potential importance we investigated the association between the BDNF C-270T polymorphism and AD in a German sample of patients with AD as well as in cognitively healthy controls.
The BDNF genotypes, which were in HardyWeinberg equilibrium, and the allele frequencies of patients with AD and controls are presented on Table  1 .
The frequency of the C/T genotype was 11.9% in patients with AD and 6.9% in the control group. The corresponding frequencies of the wild-type were 88.1% in AD and 93.1% in controls. Only one patient with early onset AD was homozygous for the T/T allele (0.5%). For statistical analysis this patient was included into the group with heterozygous subjects. When considering the whole sample and adjusting for age and sex we found a significant difference in C/T genotype or T allele frequencies between patients and controls (odds ratio (OR) 2.16 (1.04-4.48) (95% CI); P = 0.035; for genotype frequency). The BDNF C/T genotype frequency was non-significantly higher in patients with early onset AD (15.3%) compared to late onset AD (9.2%) and controls when adjusting for age. Subsequent analysis of patients with AD according to their ApoE genotype revealed that the frequency of the C/T genotype was higher in patients lacking the ApoE ⑀4 allele (n = 126; 15.3%; P = 0.015; OR = 2.61 (1.21-5.64), in particular in those with early onset AD (n = 68; 20%; P = 0.01; OR = 3.13 (1.32-7.43), compared to cognitively healthy controls. The results remained significant when considering the multiple testing situation according to the Holm procedure on a global two-sided significance level of five per cent. We also tested for interaction between the BDNF T allele and the apoE ⑀3 or ⑀4 allele, respectively and found no significant effect for both alleles. We also observed a significant negative effect between the number of T alleles inherited and the age of onset in the whole AD group after correction for the apoE genotype and sex. The age of onset was 66.7 ± 10.1 years in patients without the BDNF T allele and 61.7 ± 10.9 years in patients with one copy of the BDNF T allele (P = 0.028). In patients without the ApoE ⑀4 allele the age of onset was also significantly lower in patients with the CT genotype (59.1 ± 11 years) compared to subjects with the wild-type (65.9 ± 10.9 years) when adjusting for sex; P = 0.036.
In this report we investigated a recently determined single nucleotide polymorphism, C-270T, within the Molecular Psychiatry BDNF gene in German patients with AD and cognitively healthy controls. Considering the complete group of patients with AD, we found a significant overrepresentation of the C/T genotype in patients compared to cognitively healthy controls. The fact that the control group used in this study was younger than the AD group did not affect our findings since logistic regression analysis considered adjustment for age. In addition, we re-tested the sample when the control group was age-matched (n = 156) and obtained the same results. The risk conferred by the C/T genotype appeared to be stronger in patients with early onset AD and particularly in those lacking the ApoE ⑀4 allele as indicated by an OR of 3.13 (1.32-7.43). In addition, no association was observed in patients with late onset AD. However, based on 18 patients with the C/T genotype out of 118 patients without the ApoE ⑀4 allele, and 13 patients heterozygous for the BDNF genotype out of 65 patients with both lack of the ApoE ⑀4 allele and early onset of the disease, the results must await confirmation in a larger sample group and therefore should not be overestimated. In carriers of the BDNF T allele we observed an approximately 5 years earlier onset of the disease in all patients and a 7 years earlier onset in patients without the ApoE ⑀4 allele.
Considering the above mentioned limitations we conclude that the BDNF C-270T polymorphism or a gene nearby is a relevant genetic risk factor, particularly in patients with early onset and those without the ApoE ⑀4 allele in this German sample.
Although our results partially confirm a recent publication, which analysed the BDNF C-280T polymorphism in a Japanese population 13 they are also at variance with this study. In the recent study the authors found a significant overrepresentation of the CT genotype in patients with late onset AD, conferring a risk of 3.8 irrespective of the apoE genotype. Since the CT genotype frequencies in patients with AD are almost equal between both studies, the composition of the control groups are responsible for the differing results. In their study the CT frequency among controls was 4.2%, which contrasts to our control group showing, with 6.9% a considerable higher frequency.
Since the genotype distribution of both studies showed no departure from Hardy-Weinberg equilibrium and both studies used carefully ascertained control groups of sufficient size, we assume that the differences of the genotype distribution in controls are most likely due to population differences. Such differences may occur in populations with different ethnic background. The fact that this study observed a higher risk in patients without the ApoE ⑀4 allele and in patients with early onset AD, contrasts to the previous report which showed the highest risk in patients with late onset AD irrespective of the ApoE genotype. Most likely these differences are explained by the small sample size of both studies remaining after subgroup analysis (early onset: n = 3 vs n = 15 in this study; ApoE ⑀4 allele negative: n = 9 vs n = 18 in this study).
However, data on just 15 or 18 patients in this study also raise the possibility of false positive results and far reaching interpretations at this stage would be clearly premature. But it may be speculated that due to population differences the BDNF C/T genotype may confer variable risk to different subgroups of patients with AD. This view is supported by our finding that the presence of the C/T genotype significantly decreased the age of onset by approximately 5 years which was not observed in the previous report. Future studies are required to examine possible functional consequences of this BDNF polymorphism since two independent studies clearly showed an association between this polymorphism and AD.
In this report we observed a significant association between a BDNF polymorphism and AD in a German sample which was stronger in patients without the apoE ⑀4 allele or early onset of the disease. Although the preliminary results of this German sample have to be confirmed in a larger, independent sample, we conclude that the BDNF polymorphism, or a gene nearby, may act as a susceptibility gene particularly in patients with AD lacking the major susceptibility gene of AD, the ApoE ⑀4 allele.
Methods

Participants
The study refers to a total of 398 Caucasian subjects composed of 210 individuals with a clinical diagnosis of probable AD and 188 cognitively healthy controls. The mean age of patients with AD was 69.3 years (SD 10.4) and 38.7% were men. The corresponding values of the complete control group were 65.6 (SD 13.8) 36% men, age-matched controls 70.2 (SD 11.1) (35% men; n = 156). The patients with AD and controls were recruited at a university memory clinic from 1994 to 2001. Most subjects of the control group were cognitively unimpaired spouses of memory clinic patients or other unrelated cognitively healthy age-matched volunteers. Information on age at onset of the disease was obtained from an informant. Age at onset was defined by the appearance of first clinical symptoms. After informed consent had been obtained blood samples of each subject were taken by venous puncture. The study protocol was approved by the review board of the medical faculty, Technische Universität Mü nchen. The diagnosis of probable AD was established according to NINCDS-ADRDA criteria. 15 Cognitive impairment was assessed using the Cambridge Cognitive Examination, CAMCOG 16 or, alternatively, the Consortium to Establish a Registry for Alzheimer's disease, CERAD. 17 Both instruments incorporate the Mini Mental State Examination. 18 The MMSE was used to evaluate cognitive performance in the control group. Subjects with a MMSE score below 28 or a positive family history of dementia were excluded. All patients and controls underwent a thorough psychiatric, neurologic, and neuropsychological evaluation. The diagnostic work-up of patients included an informant interview, a chemistry survey, structural MRI imaging, and functional imaging using 18 FDG PET whenever possible.
Genotyping DNA was extracted using standard procedures. The BDNF C-270T polymorphism was genotyped as recently described 13 using the following pair of primers: BDNF-Fw 5Ј-CAG AGG AGC CAG CCC GGT GCG-3Ј and BDNF-Rev 5Ј-CTC CTG CAC CAA GCC CCA TTC-3Ј. Amplification was performed using the buffer premix H (Fail Safe PCR System; Epicentre Technologies, France), 0.5 U polymerase and 10 pmol of each primer in a final volume of 25 l. After denaturation for 3 min at 95°C, the reaction mixture was subjected to 30 cycles of 94°C for 30 s, 64°C for 30 s and 72°C for 1 min followed by a final extension at 72°C for 10 min. The 223-bp amplification product was digested at 37°C overnight with Hinf I (New England Biolabs, Frankfurt, Germany) according to the instructions of the manufacturer. The resulting DNA fragments were separated on a 4% agarose gel (Metaphor) and visualized by ethidium bromide staining. The wild-type, the BDNF C allele yielded two fragments of 127 bp and 78 bp. Heterozygous carriers with the C and T allele showed three bands at 127 bp, 78 bp, and 63 bp, whereas subjects homozygous for the T allele had two bands at 127 bp and 63 bp.
The ApoE polymorphism of each subject was determined as previously described. 19 
Statistical analysis
Differences in genotype or allele distributions between patients and controls were tested by logistic regression analysis while adjusting for age and gender. A result of the logistic regression analysis was accepted if the models of stepwise forward and backward gave the same final result. Odds ratios were calculated with exact 95% CI. The effect of the BDNFT allele on age at onset was proved by multiple linear regression analysis while adjusting for gender. Possible interactions between the BDNF T allele and the apoE ⑀4 allele were determined using logistic regression analysis with age and sex as covariates. P-values and significance considerations are two-sided and subject to a significance level of 5%.
Analyses were performed by the SPSS statistical package (version 10). Exact 95% CIs were calculated with StatXact (version 4.0.1).
